[{"id":"351db7f3-6d9a-4613-9f48-4b25eb1e0b71","acronym":"","url":"https://clinicaltrials.gov/study/NCT03894618","created_at":"2021-01-18T19:11:01.852Z","updated_at":"2024-07-02T16:34:26.954Z","phase":"Phase 1","brief_title":"SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT03894618","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" EGFR • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK fusion","tags":["EGFR • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SL-279252"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 03/26/2019","start_date":" 03/26/2019","primary_txt":" Primary completion: 05/04/2023","primary_completion_date":" 05/04/2023","study_txt":" Completion: 05/04/2023","study_completion_date":" 05/04/2023","last_update_posted":"2024-06-12"}]